Decreased skeletal muscle mitochondrial DNA in patients treated with high‐dose simvastatin
BA Schick, R Laaksonen, JJ Frohlich… - Clinical …, 2007 - Wiley Online Library
Clinical Pharmacology & Therapeutics, 2007•Wiley Online Library
Statins are generally well tolerated, but can cause myopathy 1 and have been associated
with mitochondrial abnormalities. 2, 3, 4, 5, 6 The aim of this study was to determine whether
muscle mitochondrial DNA (mtDNA) levels are altered during statin therapy. We
retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part
of a previously published 7 clinical trial of high‐dose simvastatin or atorvastatin versus
placebo. Clinical Pharmacology & Therapeutics (2007) 81, 650–653. doi: 10.1038/sj. clpt …
with mitochondrial abnormalities. 2, 3, 4, 5, 6 The aim of this study was to determine whether
muscle mitochondrial DNA (mtDNA) levels are altered during statin therapy. We
retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part
of a previously published 7 clinical trial of high‐dose simvastatin or atorvastatin versus
placebo. Clinical Pharmacology & Therapeutics (2007) 81, 650–653. doi: 10.1038/sj. clpt …
Statins are generally well tolerated, but can cause myopathy1 and have been associated with mitochondrial abnormalities.2,3,4,5,6 The aim of this study was to determine whether muscle mitochondrial DNA (mtDNA) levels are altered during statin therapy. We retrospectively quantified mtDNA in 86 skeletal muscle biopsy specimens collected as part of a previously published7 clinical trial of high‐dose simvastatin or atorvastatin versus placebo.
Clinical Pharmacology & Therapeutics (2007) 81, 650–653. doi:10.1038/sj.clpt.6100124; published online 28 February 2007
Wiley Online Library